Medtronic Pumps Confidence in MiniMed Through Performance Guarantee

Medtronic has been leading the industry in the charge toward value-based care, and its efforts have been paying off in spades, as MD+DI has recently observed. Now, the company has found yet another way to stay ahead of the curve. The company recently launched a new performance guarantee program around its MiniMed 670G insulin pump. The new program is an outcomes-based offering for payers and employers designed to mitigate costs for diabetes-related complications. With this guarantee, Medtronic said it will provide flat-fee reimbursements of up to $25,000 per pump over four years for qualifying diabetes-related inpatient hospitalization and emergency room admissions for eligible in-network patients in the United States. "The idea is to really put our money where our mouth is and really get behind the performance of our products," Suzanne Winter, vice president of the Americas region for the Diabetes Group at Medtronic, told MD+DI. The program is the result of analyzing data from clinical trials and also real-world data that shows how patients have been doing on the MiniMed 670G insulin pump, Winter said. "It is the result of our taking a look at our data from our clinical trials and also our real-world data around how the patients have been doing on their 670G The program is being offered to payers and large employers with an at-risk population, and it provides Medtronic with an opportunity to work with those partnrs to identify patients who would benefit from the MiniMed 670G...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news